Alcohol-associated liver disease death rates remain above 2018 levels

Alcohol-associated liver disease death rates and heavy drinking patterns remain above pre-pandemic benchmarks set in 2018, despite modest population-level declines between 2022 and 2024, hcplive.com reported. Public health data show that while overall metrics have eased slightly from their pandemic peaks, demographic disparities continue to widen across specific age groups and sexes.

Demographic Shifts in Women and Young Adults

Women reduced heavy drinking by 9% from 2022 to 2024, outpaces men who cut their intake by 7.7%, according to Brian Lee. However, heavy drinking among women remains about 13% above 2018 levels and is now slightly more prevalent among women than men due to lower clinical thresholds for heavy drinking. Frances Lee noted that physiological differences, including smaller body size, decreased total body water, and higher body fat percentages, lead to higher blood alcohol concentrations in women compared to men who ingest identical amounts of alcohol.

Alcohol-related cirrhosis death rates among women rose 125% from 2000 to 2023, compared to a 51.2% increase for men over the same period. Beginning in 2011, the death rate for women climbed 8.32% annually through 2022, peaking at 5.5 per 100,000 in 2021 before easing to 4.8 per 100,000 in 2023. By comparison, men’s alcohol-related cirrhosis death rates stood at 10.2 per 100,000 in 2023, still markedly higher than female rates overall.

Metabolic and Genetic Risk Factors in Younger Patients

Hospitalization data from 2016 to 2022 illustrate a distinct shift in younger cohorts, with alcohol-associated hepatitis hospitalization rates among adults aged 20 to 49 climbing 4.48% per year to reach 144.7 per 100,000. By 2020, alcohol-associated hepatitis hospitalization rates in younger adults surpassed older adults at 65.6 versus 61.3 per 100,000. Among adults aged 25 to 34, the alcohol-related cirrhosis death rate nearly doubled from 1.8 per 100,000 in 2018 to 3.4 in 2021, settling at 3.0 in 2023, where 80.3% of all cirrhosis deaths in this age group were alcohol related.

Frances Lee pointed to rising metabolic syndrome components, including obesity and diabetes, as key drivers that accelerate clinical liver disease in younger patients. Genetic polymorphisms also contribute to risk, with homozygous carriers of the PNPLA3 I148M variant who have obesity and excessive alcohol intake facing a 17.52-fold greater risk of cirrhosis than non-carriers without obesity or excessive drinking, according to UK Biobank cohort study data.

Liver Disease Trends Persist Despite Recent Declines

Brian Lee cautioned that two years of modest decline will not rapidly reverse a multi-decade trajectory of rising liver disease, particularly given that women’s increased intake predated the pandemic by at least ten years. Frances Lee added that the specific impacts of hormone levels and menopausal status on alcohol-associated liver disease progression remain understudied.